Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor

Christopher T. Wild, Joanna M. Miszkiel, Eric A. Wold, Claudia A. Soto, Chunyong Ding, Rachel M. Hartley, Mark White, Noelle Anastasio, Kathryn Cunningham, Jia Zhou

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

An impaired signaling capacity of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in the neurobehavioral processes that promote relapse vulnerability in cocaine use disorder (CUD). Restoration of the diminished 5-HT2CR signaling through positive allosteric modulation presents a novel therapeutic approach. Several new molecules with the 4-alkylpiperidine-2-carboxamide scaffold were designed, synthesized, and pharmacologically evaluated, leading to the discovery of selective 5-HT2CR positive allosteric modulators (PAMs). Compound 16 (CYD-1-79) potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells. A topographically distinct allosteric site was identified based on the newly solved 5-HT2CR structure. Compound 16 modulated 5-HT2CR-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2CR agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for CUD.

LanguageEnglish (US)
Pages288-305
Number of pages18
JournalJournal of Medicinal Chemistry
Volume62
Issue number1
DOIs
StatePublished - Oct 1 2019

Fingerprint

Receptor, Serotonin, 5-HT2C
Serotonin
Cocaine
Serotonin 5-HT2 Receptor Agonists
Allosteric Site
Recurrence
Self Administration
Walking
Rodentia
Calcium
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor. / Wild, Christopher T.; Miszkiel, Joanna M.; Wold, Eric A.; Soto, Claudia A.; Ding, Chunyong; Hartley, Rachel M.; White, Mark; Anastasio, Noelle; Cunningham, Kathryn; Zhou, Jia.

In: Journal of Medicinal Chemistry, Vol. 62, No. 1, 01.10.2019, p. 288-305.

Research output: Contribution to journalArticle

@article{85594fcb469d45b9b272a11a99df6b33,
title = "Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor",
abstract = "An impaired signaling capacity of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in the neurobehavioral processes that promote relapse vulnerability in cocaine use disorder (CUD). Restoration of the diminished 5-HT2CR signaling through positive allosteric modulation presents a novel therapeutic approach. Several new molecules with the 4-alkylpiperidine-2-carboxamide scaffold were designed, synthesized, and pharmacologically evaluated, leading to the discovery of selective 5-HT2CR positive allosteric modulators (PAMs). Compound 16 (CYD-1-79) potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells. A topographically distinct allosteric site was identified based on the newly solved 5-HT2CR structure. Compound 16 modulated 5-HT2CR-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2CR agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for CUD.",
author = "Wild, {Christopher T.} and Miszkiel, {Joanna M.} and Wold, {Eric A.} and Soto, {Claudia A.} and Chunyong Ding and Hartley, {Rachel M.} and Mark White and Noelle Anastasio and Kathryn Cunningham and Jia Zhou",
year = "2019",
month = "10",
day = "1",
doi = "10.1021/acs.jmedchem.8b00401",
language = "English (US)",
volume = "62",
pages = "288--305",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor

AU - Wild, Christopher T.

AU - Miszkiel, Joanna M.

AU - Wold, Eric A.

AU - Soto, Claudia A.

AU - Ding, Chunyong

AU - Hartley, Rachel M.

AU - White, Mark

AU - Anastasio, Noelle

AU - Cunningham, Kathryn

AU - Zhou, Jia

PY - 2019/10/1

Y1 - 2019/10/1

N2 - An impaired signaling capacity of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in the neurobehavioral processes that promote relapse vulnerability in cocaine use disorder (CUD). Restoration of the diminished 5-HT2CR signaling through positive allosteric modulation presents a novel therapeutic approach. Several new molecules with the 4-alkylpiperidine-2-carboxamide scaffold were designed, synthesized, and pharmacologically evaluated, leading to the discovery of selective 5-HT2CR positive allosteric modulators (PAMs). Compound 16 (CYD-1-79) potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells. A topographically distinct allosteric site was identified based on the newly solved 5-HT2CR structure. Compound 16 modulated 5-HT2CR-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2CR agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for CUD.

AB - An impaired signaling capacity of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in the neurobehavioral processes that promote relapse vulnerability in cocaine use disorder (CUD). Restoration of the diminished 5-HT2CR signaling through positive allosteric modulation presents a novel therapeutic approach. Several new molecules with the 4-alkylpiperidine-2-carboxamide scaffold were designed, synthesized, and pharmacologically evaluated, leading to the discovery of selective 5-HT2CR positive allosteric modulators (PAMs). Compound 16 (CYD-1-79) potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells. A topographically distinct allosteric site was identified based on the newly solved 5-HT2CR structure. Compound 16 modulated 5-HT2CR-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2CR agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for CUD.

UR - http://www.scopus.com/inward/record.url?scp=85059508564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059508564&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b00401

DO - 10.1021/acs.jmedchem.8b00401

M3 - Article

VL - 62

SP - 288

EP - 305

JO - Journal of Medicinal Chemistry

T2 - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -